{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive&page=3",
    "query": {
      "condition": "Hormone Receptor Positive",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 421,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T19:21:12.941Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02395627",
      "title": "Reversing Therapy Resistance With Epigenetic-Immune Modification",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2015-05-04",
      "completion_date": "2019-06-08",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02395627"
    },
    {
      "nct_id": "NCT05966584",
      "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant or AIs) and PI3K inhibition (alpelisib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2023-07-06",
      "completion_date": "2024-08-02",
      "has_results": true,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05966584"
    },
    {
      "nct_id": "NCT01225172",
      "title": "Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-754807",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2010-12-31",
      "completion_date": "2014-11-30",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225172"
    },
    {
      "nct_id": "NCT07558733",
      "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HR+ HER2- Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Serabelisib",
          "type": "DRUG"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Faeth Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-04-22",
      "completion_date": "2033-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07558733"
    },
    {
      "nct_id": "NCT04875351",
      "title": "Breast Cancer Index (BCI) Registry",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Biotheranostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3465,
      "start_date": "2021-04-14",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 105,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 84 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04875351"
    },
    {
      "nct_id": "NCT04305496",
      "title": "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced (Inoperable) or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 818,
      "start_date": "2020-04-16",
      "completion_date": "2026-06-22",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 22,
      "location_summary": "Gilbert, Arizona • Orange, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305496"
    },
    {
      "nct_id": "NCT04379570",
      "title": "Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "HER2 Negative Breast Carcinoma",
        "Hormone Receptor Positive Breast Carcinoma",
        "Invasive Breast Carcinoma",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage III Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Text Message-based Navigation Intervention",
          "type": "OTHER"
        },
        {
          "name": "Motivational Interviewing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1167,
      "start_date": "2021-02-15",
      "completion_date": "2027-10-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 526,
      "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379570"
    },
    {
      "nct_id": "NCT05447910",
      "title": "Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Adenocarcinoma",
        "Invasive Breast Carcinoma",
        "Resectable Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2022-07-21",
      "completion_date": "2023-09-27",
      "has_results": false,
      "last_update_posted_date": "2025-06-15",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05447910"
    },
    {
      "nct_id": "NCT02246621",
      "title": "A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 493,
      "start_date": "2014-11-06",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 20,
      "location_summary": "Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246621"
    },
    {
      "nct_id": "NCT02942355",
      "title": "Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Female Breast Carcinoma",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2016-12-07",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-11-17T19:21:12.941Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02942355"
    }
  ]
}